Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Reports Q4 and FY 2023 Financial Results and Announces Capped Call Unwinding
Summary
Apellis Pharmaceuticals, Inc. reported its Q4 and full year 2023 financial results, highlighting significant revenue growth driven by SYFOVRE and EMPAVELI, despite reporting a net loss for the period. The company also announced the unwinding of a portion of its capped call transactions, expecting to receive approximately $100 million in net cash proceeds. The exhibit details the company's financial performance, business highlights, and forward-looking statements.
Profitelligence Alerts
Get alerts for APLS
Be first to know when Apellis Pharmaceuticals Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing novel therapeutic compounds to address complement-mediated diseases. The primary focus of Apellis is to pioneer medicines leveraging targeted inhibition of the complement system, a key component of the immune system that plays a crucial role in a variety of diseases. The company's flagship product, targeting diseases such as geographic atrophy and paroxysmal nocturnal hemoglobinuria (PNH), highlights its commitment to addressing unmet medical needs with innovative treatments. Apellis Pharmaceuticals operates in the highly competitive pharmaceutical and biotechnology industry, collaborating with healthcare providers and research institutions to advance clinical treatment options. Headquartered in Waltham, Massachusetts, its contributions to medical science are significant, paving the way for advancements in immunology and therapy development. As a publicly traded entity, Apellis influences the healthcare sector by enhancing treatment paradigms and offering new hope for patients with chronic and debilitating conditions.
Official SEC Documents
Advertisement